Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK-pathway-driven cancers, today announced positive, updated efficacy and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback